NovaBridge Biosciences Cash Flow Conversion Efficiency
NovaBridge Biosciences cash flow conversion efficiency. Based on the latest financial reports, NovaBridge Biosciences (NBP) has a cash flow conversion efficiency ratio of -0.082x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.40 Million) by net assets ($201.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NovaBridge Biosciences (2017–2025)
Cash flow conversion efficiency of NovaBridge Biosciences from 2017 to 2025. This chart illustrates how NovaBridge Biosciences's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NBP stock price for real-time trading data and today's change.
NovaBridge Biosciences Cash Flow Conversion Ratio Explained
NovaBridge Biosciences cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NovaBridge Biosciences Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NovaBridge Biosciences ranked by their cash flow conversion efficiency. Also see NBP market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ugro Capital Limited
NSE:UGROCAP
|
-0.019x |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
N/A |
|
Teo Seng Capital Bhd
KLSE:7252
|
-0.015x |
|
Sungshin Cemen
KO:004980
|
-0.026x |
|
Lin Horn Technology Co Ltd
TWO:5464
|
0.058x |
|
Shinsegae I&C
KO:035510
|
0.072x |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
-0.011x |
|
Data International Co Ltd
TWO:5432
|
0.095x |
Annual Cash Flow Conversion Efficiency for NovaBridge Biosciences (2017–2025)
The table below shows the annual cash flow conversion efficiency of NovaBridge Biosciences from 2017 to 2025. Review how much free cash does NovaBridge Biosciences generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $33.02 Million | $-20.60 Million | -0.624x | -138.35% |
| 2024-12-31 | $1.47 Billion | $-384.29 Million | -0.262x | +12.85% |
| 2023-12-31 | $242.58 Million | $-72.85 Million | -0.300x | +18.08% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | +73.05% |
| 2021-12-31 | $715.33 Million | $-973.09 Million | -1.360x | -1863.86% |
| 2020-12-31 | $5.62 Billion | $433.56 Million | 0.077x | -81.92% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy… Read more